Ticker > Company >

Tatva Chintan Pharma share price

Tatva Chintan Pharma Chem Ltd.

NSE: TATVA BSE: 543321 SECTOR: Chemicals  178k   479   88

942.00
+15.25 (1.65%)
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 948

Today's Low

₹ 862.85

52 Week High

₹ 1195.05

52 Week Low

₹ 610

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2203.53 Cr.

Enterprise Value

2180.83 Cr.

No. of Shares

2.34 Cr.

P/E

6738.2

P/B

3.05

Face Value

₹ 10

Div. Yield

0.11 %

Book Value (TTM)

₹  308.36

CASH

36.97 Cr.

DEBT

14.27 Cr.

Promoter Holding

72.02 %

EPS (TTM)

₹  0.14

Sales Growth

-6.05%

ROE

4.77 %

ROCE

6.91%

Profit Growth

-27.47 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-6.05%
3 Year9.15%
5 Year13.29%

Profit Growth

1 Year-27.47%
3 Year-17.02%
5 Year7.77%

ROE%

1 Year4.77%
3 Year14.5%
5 Year23.34%

ROCE %

1 Year6.91%
3 Year13.4%
5 Year18.97%

Debt/Equity

0.0197

Price to Cash Flow

21.44

Interest Cover Ratio

7.3499

CFO/PAT (5 Yr. Avg.)

0.752829979137084

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 72.02 0.00
Dec 2024 72.02 0.00
Sep 2024 72.02 0.00
Jun 2024 72.02 0.00
Mar 2024 72.02 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 155.986 Cr.
  • Company is virtually debt free.
  • Company has a healthy liquidity position with current ratio of 3.1827.
  • The company has a high promoter holding of 72.02%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.55927837821784.

 Limitations

  • The company has shown a poor profit growth of -17.0173466633757% for the Past 3 years.
  • The company has shown a poor revenue growth of 9.15193466896298% for the Past 3 years.
  • The company is trading at a high PE of 6738.2.
  • The company is trading at a high EV/EBITDA of 75.7692.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 93.93 93.81 80.96 84 107.65
Total Expenditure 79.73 86.11 76.36 78.35 99.75
Operating Profit 14.2 7.7 4.6 5.65 7.9
Other Income 4.53 1.42 0.81 0.04 1.3
Interest 0.22 0.31 0.17 0.42 0.39
Depreciation 6.23 6.66 6.81 6.92 7.26
Exceptional Items 0 0 0 0 0
Profit Before Tax 12.28 2.14 -1.58 -1.65 1.55
Tax 4.03 0.63 -0.47 -0.49 0.46
Profit After Tax 8.25 1.51 -1.11 -1.17 1.1
Adjusted EPS (Rs) 3.53 0.64 -0.47 -0.5 0.47

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 253.84 291.19 427.81 403.04 378.68
Total Expenditure 201.14 225.8 321.81 348.23 311.66
Operating Profit 52.7 65.39 106.01 54.82 67.01
Other Income 0.56 5.1 10.63 5.68 7.51
Interest 4.25 4.41 5.19 8.52 6.66
Depreciation 4.79 6.73 8.18 9.55 25.6
Exceptional Items 0 0 0 -3.59 0
Profit Before Tax 44.22 59.35 103.27 38.83 42.27
Tax 9.25 7.99 7.28 -1.63 12.92
Net Profit 34.96 51.36 95.99 40.47 29.35
Adjusted EPS (Rs.) 17.41 25.57 43.31 18.26 12.55

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 8.04 20.09 22.17 22.17 23.39
Total Reserves 106.41 141.85 446.71 482.62 702.49
Borrowings 38.71 26.76 13.11 4.23 0.64
Other N/C liabilities 4.89 4.06 -8.05 -15.26 -10.96
Current liabilities 87.26 127.08 193.55 246.58 94.56
Total Liabilities 245.31 319.83 667.49 740.34 810.11
Assets
Net Block 111.18 120.45 159.61 196.22 426.87
Capital WIP 4.89 9.81 51.49 230.74 72.93
Intangible WIP 0 0 0 0 3.61
Investments 0.67 0.67 0.67 0.67 0.67
Loans & Advances 0.17 0.3 2.09 2.66 4.26
Other N/C Assets 0 0 0.51 0.55 0.83
Current Assets 128.4 188.61 453.12 309.49 300.95
Total Assets 245.31 319.83 667.49 740.34 810.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 44.22 59.35 103.27 38.83 42.27
Adjustment 8.2 6.92 9.64 15.82 28.17
Changes in Assets & Liabilities -20.4 -37.55 -75.18 -23.18 40.58
Tax Paid -7.39 -9.82 -17.97 -7.74 -8.24
Operating Cash Flow 24.64 18.91 19.76 23.73 102.78
Investing Cash Flow -40.18 -20.61 -196.72 -101.13 -120.52
Financing Cash Flow 9.7 -4.72 235.01 37.82 30.54
Net Cash Flow -5.85 -6.42 58.05 -39.59 12.8

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 72.02 72.02 72.02 72.02 72.02
ajay mansukhlal patel 17.10 17.10 17.10 17.10 17.10
ajay mansukhlal patel (hu... 3.06 3.06 3.06 3.06 3.06
chintan n shah (huf) 1.91 1.91 1.91 1.91 1.91
chintan nitinkumar shah 20.94 20.94 20.94 20.94 20.94
darshana nitinkumar shah 0.17 0.17 0.17 0.17 0.17
kajalben shekharkumar som... 0.93 0.93 0.93 0.93 0.93
priti ajay patel 3.85 3.85 3.85 3.85 3.85
shekhar rasiklal somani 23.07 23.07 23.07 23.07 23.07
shital chintan shah 0.99 0.99 0.99 0.99 0.99
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 27.98 27.98 27.98 27.98 27.98
goldman sachs funds - gol... 2.30 2.40 2.54 2.59 2.59
icici prudential smallcap... 2.01 1.92 1.81 2.03 2.03
llp 0.01 0.02 0.03 0.02 0.03
nippon life india trustee... 5.90 5.90 4.31 3.97 3.31
sbi magnum midcap fund 2.77 2.77 - - -
mirae asset aggressive hy... 1.64 - - - -

Annual Reports

Title Action
Annual Report 2023
Annual Report 2022
Annual Report 2021

Ratings & Research Reports

TYPE AGENCY ACTION
Credit CRISIL
Credit CRISIL
TYPE AGENCY ACTION
No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY24
Concall Q4FY22
Concall Q3FY24
Concall Q3FY22
Concall Q2FY24
Concall Q1FY22
TYPE QUARTER ACTION
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY22
Presentation Q3FY24
Presentation Q3FY22
Presentation Q2FY24
Presentation Q1FY23

Company News

Tatva Chintan Pharma Stock Price Analysis and Quick Research Report. Is Tatva Chintan Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Tatva Chintan Pharma stock price today is Rs 944.8. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Tatva Chintan Pharma . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Tatva Chintan Pharma has a PE ratio of 6758.22603719599 which is high and comparatively overvalued .

  • Share Price: - The current share price of Tatva Chintan Pharma is Rs 944.8. One can use valuation calculators of ticker to know if Tatva Chintan Pharma share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Tatva Chintan Pharma has ROA of 3.7857 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Tatva Chintan Pharma has a Current ratio of 3.1827 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Tatva Chintan Pharma has a ROE of 4.7695 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Tatva Chintan Pharma has a Debt to Equity ratio of 0.0197 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Tatva Chintan Pharma has reported revenue growth of -6.0457 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Tatva Chintan Pharma for the current financial year is 17.6968762296099 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Tatva Chintan Pharma is Rs 2 and the yield is 0.1062 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Tatva Chintan Pharma is Rs 0.1398 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Tatva Chintan Pharma in Ticker for free. Also, one can get the intrinsic value of Tatva Chintan Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Tatva Chintan Pharma
X